Sometimes all it takes to wake up the buyers is some hot news and a slow of a decline. For ages, Jim Cramer has said that he is concerned about the market because of the most important group out there—the transports.
Finally on Thursday, the "Mad Money" host saw some positive signs that the formerly hideous transports have a little bit of life left.
There was also breaking news that Dick Costolo, the CEO of Twitter, will resign, effective July 1. Cramer breathed a sigh of relief with this news, as he considers it to be the best, most poorly run company that he knows. He said this not to be mean, but because any company that is talked about this much and has so many investors leaving it because of mismanagement has to be poorly run.
"It is a hidden diamond that seemed to be on the verge of being seen as a cubic zirconium because of an almost universal acknowledgement by everyone I know that the CEO was in over his head. I used to say the only way this company could get better is to call ABC—anybody but Costolo," the "Mad Money" host said.
Cramer viewed the resignation and statement that Twitter still anticipates earnings to be in line with previous forecasts, as just another boost of the fact that investors should own the stock. Now is the time to own the stock while the company fixes itself up, or prepares to put itself up for sale. He still thinks there is a chance for improvement at Twitter under a new CEO, or under the umbrella of another company.
And while the Twitter news was red-hot after the bell, it is what happened during the day of trading that really makes the difference. Thus, Cramer focused on the importance of the larger theme of how transports will impact investor portfolios.
"I think these good things are happening because FedEx is starting to see business improve overseas. I say that because the U.S. has been on firm footing for some time. It's Europe and Asia that have been real downers," Cramer said.
Thus, the leg up in the stock shows that there could be a possibility of a worldwide recovery coming.
Read More Cramer: The right time to buy Twitter
What the heck is Cramer supposed to make out of the breathtaking Axovant Sciences? It hit the tape as the biggest biotech IPO ever on Thursday, and skyrocketed 99 percent right out of the gate.
Axovant went public at $15 on Thursday, and closed at $29—which makes Cramer a bit worried that things have gotten ahead of themselves with the stock because the target end market is so large. The company currently has one drug in its pipeline, RVT-101, which is an orally administered therapy designed to help patients with Alzheimer's disease.
Given the fact that GlaxoSmithKline sold the drug to Axovant for $5 million upfront, along with a few milestone payments and royalties, could it really be worth the current valuation of Axovant at $2.2 billion?
To make the company even more interesting, Axovant's CEO, Vivek Ramaswamy, is just 29 years old and was featured in Forbes' 30 Under 30 list last year. As a former partner at QVT Financial, he left the firm and founded Roivant Sciences, sits on the board of OnCore Biopharma and is chairman of the board of Tekmira Pharmaceuticals. He also achieved a degree in biology from Harvard College, and J.D. degree from Yale Law School—while working at QVT Financial.
Is Axovant's drug the real deal? To find out more about the company's trajectory, Cramer spoke with Ramaswamy.
"We believe we are only one additional phase 3 study away from the approval of this drug on a global basis," Ramaswamy added.
And while Cramer has seen some positive signs of recovery in the transports, he is still worried about the impact of the Fed tightening in the near future. At this point, all roads lead to a low-growth economy.
Either the economy will be too weak for the Fed to raise rates, or they will raise rates to slow down the economy. This means that Cramer wants investors to be in the kind of secular growth stocks that can thrive during a slowdown.
Health care cost containment plays are right on target for Cramer, as an aging population and increase in medical care thanks to the Affordable Care Act will increase health care costs. So far this week, Cramer has focused on Rite Aid, Cardinal Health, McKesson.
The next company that is right in the sweet spot is AmerisourceBergen. And while the company has a smaller market cap compared to some of the other companies that Cramer has highlighted, it has a big impact thanks to partnerships with Walgreens and Express Scripts.
But it is the entire wholesale drug distribution industry that really has Cramer salivating. These are the companies that will complement investor portfolios as a health-care cost-containment play.
"If you want a drug distributor that's differentiated itself from the pack, I say take a page from the 'Jackson Five', because it's as easy as ABC, AmerisourceBergen," Cramer said.
In addition to Axovant's IPO on fire, the biotech group was flying high on Thursday. And, there was some very positive news released from Cramer-fave Isis Pharmaceuticals.
Now that the biotech group has bounced back, Cramer thinks the upside to Isis could be enormous. This company led the way for antisense technology that can change the RNA in cells in order to fix issues caused by genetic abnormalities.
With 38 drugs in development, Cramer considers it to have one of the best pipelines in the business. On Thursday investors heard terrific data on one of these drugs, which is a treatment for spinal muscular atrophy, the leading cause of infantile death worldwide.
To find out more, Cramer spoke with Isis Pharmaceuticals CEO Dr. Stanley Crooke.
"Many of these babies when they enter the trial can't even move a toe, or move a finger. So, when we are able to prolong these babies' lives, and certainly the data suggests that we may be doing that, and make the muscles stronger, they're able to do things that SMA babies haven't been able to do before," Dr. Crooke said.
Take one look at some of the huge moves in the biotech group lately, and many investors assume that it is pure insanity. Not Jim Cramer! In fact, these moves make complete sense to him.
"They're not crazy because, for whatever reason, the older line pharmaceutical companies seem congenitally incapable of developing huge new drugs, while these younger companies seem to do it as a matter of course," the "Mad Money" host said.
"Given the paucity of new drugs that the old pharma companies are inventing, I wonder how these two biotechs can even stay public long enough to develop what could very well be the next Pharmassets, Regenerons or Pharmacyclics," Cramer added.
Meaning, Cramer definitely does not consider these crazy gains to be insane. To him, they are the definition of sanity, which is exactly why he continues to feature the biotechs and recommend them.
Ultimately, Cramer thinks these little biotech companies are the answer to the stale old pharmaceutical companies that have a good balance sheet, but no growth. Perhaps they should be your answer, too.
In the Lightning Round, Cramer gave his take on a few caller favorite stocks:
Medtronic PLC: "Medtronic is terrific. I love the inversion, I love their acquisitions. I think MDT should be bought, that's the right call."
DCP Midstream: "I'm worried about that yield. That yield tells me that something may not be that great about that here. I do own a high yielder for my charitable trust, and that is Energy Transfer Partners. I have a very good feel for that one. That's the one I think you should be in."